Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Granules India to get...

    Granules India to get Rs 318 crore from IFC to set up new plant in Vishakhapatnam

    Written by savita thakur thakur Published On 2017-02-23T10:41:30+05:30  |  Updated On 13 Oct 2022 10:42 AM IST

    International Finance Corporation (IFC), an arm of world Band is planning to invest 47.5 million dollars (Rs 318 crore) to Granules India Limited, an Indian pharmaceutical manufacturing company based in Hyderabad.


    The investment fund will help the Granules India to set up a plant in Vishakhapatnam, expanding existing capacities and investing in R&D to improve its product mix in favour of higher value-added products. This will be the fourth investment made by IFC in Granules India.


    The total cost of the project is estimated to be 84 million dollars, of which International Finance Corp (IFC) will invest 47.5 million dollars and the remaining will come through through equity and internal accruals.


    Granules has factories near Hyderabad and Vishakhapatnam, along with an R&D and manufacturing facility in Virginia, US. The company, through its joint ventures, also has one plant in China and another plant in Vishakhapatnam.


    The Company manufactures tablets, Pharmaceutical Formulation Intermediates (PFIs) and active pharmaceutical ingredients (APIs) which are distributed in over 50 countries.


    Earlier in 2007, IFC had made an equity investment of Rs 24.3 crore in Granules, Reports VCCircle.


    IFC has an active direct private equity-style investment practice in India. It also lends to firms and has an active limited partner, or LP, portfolio in India where it backs Private equity (PE) and Venture capital (VC) funds.


    Except Granules India, IFC has invested in Glenmark Pharmaceuticals, Jubilant Pharma and Vivimed Labs, among others.


    84 million dollarsfundGranules IndiaInternational Finance CorporationInvestmentnew plantRs 318 crorevishakhapatnamworld bank
    Source : With inputs

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    savita thakur thakur
    savita thakur thakur
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok